^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    GBP5 (Guanylate Binding Protein 5)

    i
    Other names: GBP5, Guanylate Binding Protein 5, Guanine Nucleotide-Binding Protein 5, Guanylate-Binding Protein 5, GTP-Binding Protein 5, GBP-TA Antigen, GBP-5
    2ms
    Differential Transcriptomic Features of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis with and Without Extrapulmonary Lesions in an East Asian Population. (PubMed, Biomedicines)
    These findings elucidate the mechanisms underlying granuloma formation in sarcoidosis and demonstrate the differential transcriptomic features of PBMCs in patients with and without EPL. The upregulation of IFNG and IFNLR1 may be related to EPL development and could serve as potential therapeutic targets for sarcoidosis.
    Journal
    |
    JAK2 (Janus kinase 2) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CLEC7A (C-Type Lectin Domain Containing 7A) • GBP5 (Guanylate Binding Protein 5) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • MMP9 (Matrix metallopeptidase 9) • CD40LG (CD40 ligand) • IL15 (Interleukin 15) • IL1B (Interleukin 1, beta) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    2ms
    GBP1 as a machine learning-prioritized biomarker and therapeutic target for epstein-barr virus-induced clear cell renal cell carcinoma: multi-omics causal validation. (PubMed, Int J Surg)
    This work reveals a causal relationship between EBV infection and ccRCC pathogenesis, establishing GBP1 as a top-priority candidate molecule through a multi-level, multi-dimensional evidence framework. Drug prediction and molecular docking suggest finasteride as a potential inhibitor of GBP1, offering new strategies for the precise prevention and treatment of ccRCC.
    Journal
    |
    GBP5 (Guanylate Binding Protein 5) • GBP1 (Guanylate Binding Protein 1) • IFI16 (Interferon Gamma Inducible Protein 16) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • RECQL (RecQ Like Helicase)
    |
    finasteride
    4ms
    GBP5 as a prognostic biomarker associated with immune cell infiltration, migration and invasion in clear cell renal cell carcinoma. (PubMed, Oncol Lett)
    Cellular experiments demonstrated that GBP5 regulates the migration and invasion of renal cancer cells. Overall, GBP5 shows potential as a prognostic indicator and a candidate target for immunotherapy in patients with ccRCC.
    Journal • IO biomarker
    |
    GBP5 (Guanylate Binding Protein 5)
    5ms
    Expression and prognosis of CXCL13 in uterine corpus endometrial carcinoma based on bioinformatics analysis. (PubMed, Discov Oncol)
    The above comprehensive analyses suggest that CXCL13 may serve as a potential prognostic biomarker for UCEC, specifically for early-stage UCEC.
    Journal
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • GZMB (Granzyme B) • GBP5 (Guanylate Binding Protein 5) • CCL18 (C-C Motif Chemokine Ligand 18)
    5ms
    Distinct Inflammatory Responses of hiPSC-Derived Endothelial Cells and Cardiomyocytes to Cytokines Involved in Immune Checkpoint Inhibitor-Associated Myocarditis. (PubMed, Cells)
    These results reposition endothelial dysfunction, rather than cardiomyocyte injury alone, as a central mechanism in ICI-induced myocarditis. Modulating endothelial inflammasome activation, particularly via AIM2 inhibition, could offer a novel strategy to mitigate cardiac toxicity while preserving antitumor efficacy.
    Journal • Checkpoint inhibition • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • GZMB (Granzyme B) • NLRC5 (NLR Family CARD Domain Containing 5) • GBP5 (Guanylate Binding Protein 5) • IL1B (Interleukin 1, beta) • GSDMD (Gasdermin D)
    7ms
    Guanylate-binding protein 5: a promising biomarker and therapeutic target. (PubMed, Infect Immun)
    This review provides a comprehensive synthesis of GBP5 functions across infectious diseases, cancer, immune disorders, and inflammation, with dedicated analysis of its context-dependent functional variability in distinct immune landscapes, genetic backgrounds, and disease progression stages. This systematic evaluation provides a critical foundation for future research, highlighting GBP5's promise as both a biomarker and therapeutic target in precision medicine.
    Review • Journal
    |
    GBP5 (Guanylate Binding Protein 5)
    7ms
    A randomized, open-label, multicenter clinical study comparing the combination of epalorlimovalizumab and bevacizumab with TAS-102 versus bevacizumab combined with TAS-102 in the second-line treatment of advanced colorectal cancer (ChiCTR2500106797)
    P4, N=84, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GBP5 (Guanylate Binding Protein 5) • STAT1 (Signal Transducer And Activator Of Transcription 1) • APOE (Apolipoprotein E) • GBP1 (Guanylate Binding Protein 1) • TAP1 (Transporter 1) • GBP4 (Guanylate Binding Protein 4) • MX1 (MX Dynamin Like GTPase 1) • SDC2 (Syndecan 2)
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    10ms
    Integrating Single-Cell and Bulk RNA Sequencing Data to Explore Sphingolipid Metabolism Molecular Signatures in Ovarian Cancer Prognosis: an Original Study. (PubMed, Int J Med Sci)
    Our model effectively identifies high-risk patients and provides a reference for prognosis prediction using SRG signature. Moreover, hub gene GBP5 acts as a tumor inhibitory factor and regulates the chemosensitivity of oxaliplatin, gemcitabine, and sorafenib in OC.
    Journal
    |
    CD8 (cluster of differentiation 8) • GBP5 (Guanylate Binding Protein 5)
    |
    gemcitabine • sorafenib • oxaliplatin
    11ms
    Role of guanylate-binding protein 5 in inflammatory diseases, immune diseases, cancers, and its potential therapeutic implications. (PubMed, Inflammopharmacology)
    This article examines the role of GBP5 in inflammation, autoimmune disorders, and malignancies while also exploring its potential therapeutic implications. We aim to deepen our understanding of GBP5 and assess its prospective applications in clinical diagnosis and treatment.
    Review • Journal
    |
    IFNG (Interferon, gamma) • GBP5 (Guanylate Binding Protein 5)
    11ms
    Transcriptional and microbial profile of gastric cancer patients infected with Epstein-Barr virus. (PubMed, Front Oncol)
    These findings suggest a complex interaction between the host (EBV+ GC) and the microbiota, possibly influencing cancer progression, and offering potential therapeutic targets such as microbiota modulation or gene regulation. Comparing with EBV- samples further highlights the specific impact of EBV and the microbiota on gastric cancer pathogenesis.
    Journal
    |
    ICAM1 (Intercellular adhesion molecule 1) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • GBP5 (Guanylate Binding Protein 5) • IL32 (Interleukin 32) • TNFSF10 (TNF Superfamily Member 10) • GBP4 (Guanylate Binding Protein 4)
    11ms
    Regulation of Exosomal miR-320d/FAM49B Axis by Guanylate Binding Protein 5 Promotes Cell Growth and Tumor Progression in Oral Squamous Cell Carcinoma. (PubMed, J Oral Pathol Med)
    Our study suggests that GBP5 downregulated exosomal miR-320d may trigger FAM49B expression and facilitate OSCC tumor growth and progression.
    Journal
    |
    GBP5 (Guanylate Binding Protein 5)
    |
    paclitaxel
    1year
    Epidermal growth factor dampens pro-inflammatory gene expression induced by interferon-gamma in global transcriptome analysis of keratinocytes. (PubMed, BMC Genomics)
    Our findings suggest that the pro-inflammatory IFN-γ-induced transcriptome may be globally attenuated by EGF in keratinocytes, supporting an immunomodulatory role of EGF in the skin. These studies provide insights for the non-canonical immunomodulatory role of EGF signaling and why blocking EGFR signaling (e.g., with EGFRIs) can cause cutaneous inflammation.
    Clinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • EGF (Epidermal growth factor) • GBP5 (Guanylate Binding Protein 5) • NLRP3 (NLR Family Pyrin Domain Containing 3)